Do Breast Cancer Patients With Chemotherapy-induced Peripheral Neuropathy Have an Increased Risk of Radiation Dermatitis?

IF 1.8 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

In vivo Pub Date : 2025-07-01 DOI:10.21873/invivo.14019

Dirk Rades, Martin Ballegaard

{"title":"Do Breast Cancer Patients With Chemotherapy-induced Peripheral Neuropathy Have an Increased Risk of Radiation Dermatitis?","authors":"Dirk Rades, Martin Ballegaard","doi":"10.21873/invivo.14019","DOIUrl":null,"url":null,"abstract":"Background/aim: Patients with breast cancer scheduled for irradiation may present with peripheral neuropathy (PNP) caused by preceding taxane-based chemotherapy. Chemotherapy-related toxicity was suggested to be associated with a lower individual DNA repair capacity. A similar association was described for radiation-related toxicity. We investigated whether patients with taxane-induced PNP have an increased risk of radiation dermatitis.Patients and methods: In a retrospective cohort of 129 patients irradiated for breast cancer following taxane-based chemotherapy, PNP plus 14 characteristics were evaluated for associations with grade ≥2 radiation dermatitis.Results: No, mild, and moderate to severe PNP were associated with grade ≥2 dermatitis rates of 22.2%, 27.7%, and 37.8% (p=0.123). On multivariate analysis, grade ≥2 dermatitis was significantly associated with normo-fractionated radiotherapy (p=0.032) and a body mass index ≥30 kg/m2 (p<0.001).Conclusion: A significant association between severity of PNP and grade ≥2 radiation dermatitis was not found, although grade ≥2 dermatitis occurred more frequently in patients with moderate to severe PNP.","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 4","pages":"2236-2242"},"PeriodicalIF":1.8000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223629/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"In vivo","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/invivo.14019","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: Patients with breast cancer scheduled for irradiation may present with peripheral neuropathy (PNP) caused by preceding taxane-based chemotherapy. Chemotherapy-related toxicity was suggested to be associated with a lower individual DNA repair capacity. A similar association was described for radiation-related toxicity. We investigated whether patients with taxane-induced PNP have an increased risk of radiation dermatitis.

Patients and methods: In a retrospective cohort of 129 patients irradiated for breast cancer following taxane-based chemotherapy, PNP plus 14 characteristics were evaluated for associations with grade ≥2 radiation dermatitis.

Results: No, mild, and moderate to severe PNP were associated with grade ≥2 dermatitis rates of 22.2%, 27.7%, and 37.8% (p=0.123). On multivariate analysis, grade ≥2 dermatitis was significantly associated with normo-fractionated radiotherapy (p=0.032) and a body mass index ≥30 kg/m² (p<0.001).

Conclusion: A significant association between severity of PNP and grade ≥2 radiation dermatitis was not found, although grade ≥2 dermatitis occurred more frequently in patients with moderate to severe PNP.

查看原文本刊更多论文

化疗引起的周围神经病变乳腺癌患者发生放射性皮炎的风险增加吗？

背景/目的：计划接受放射治疗的乳腺癌患者可能会出现周围神经病变（PNP），这是由于之前紫杉烷类化疗引起的。化疗相关毒性被认为与较低的个体DNA修复能力有关。与辐射有关的毒性也有类似的关联。我们调查了紫杉烷诱导的PNP患者是否增加了放射性皮炎的风险。患者和方法：在一项回顾性队列研究中，129名接受紫杉烷化疗后接受乳腺癌放疗的患者，评估PNP加14个特征与≥2级放射性皮炎的相关性。结果：无、轻度和中度至重度PNP与≥2级皮炎发生率相关，分别为22.2%、27.7%和37.8% （p=0.123）。在多因素分析中，≥2级皮炎与正常分级放疗（p=0.032）和体重指数≥30 kg/m2显著相关(p结论：PNP的严重程度与≥2级放射性皮炎之间没有显著相关性，尽管≥2级皮炎在中重度PNP患者中发生的频率更高。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

In vivo 医学-医学：研究与实验

CiteScore

4.20

自引率

4.30%

发文量

330

审稿时长

3-8 weeks

期刊介绍： IN VIVO is an international peer-reviewed journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frames of physiology, pathology and disease management. The topics of IN VIVO include: 1. Experimental development and application of new diagnostic and therapeutic procedures; 2. Pharmacological and toxicological evaluation of new drugs, drug combinations and drug delivery systems; 3. Clinical trials; 4. Development and characterization of models of biomedical research; 5. Cancer diagnosis and treatment; 6. Immunotherapy and vaccines; 7. Radiotherapy, Imaging; 8. Tissue engineering, Regenerative medicine; 9. Carcinogenesis.